Detection and quantification of plasma amyloid-β by selected reaction monitoring mass spectrometry

Analytica Chimica Acta

Volumn 840, Issue , 2014, Pages 1-9

  Kim, Jun Seok ^a   Ahn, Hee Sung ^a,b   Cho, Soo Min ^a   Lee, Ji Eun ^a   Kim, YoungSoo ^a   Lee, Cheolju ^a,b  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

Author keywords

Alzheimer's disease; Amyloid ; High pH reversed phase liquid chromatography; Plasma; Selected reaction monitoring; Surrogate peptide

Indexed keywords

ANTIBODIES; BIOCHEMISTRY; CEREBROSPINAL FLUID; GLYCOPROTEINS; LIQUID CHROMATOGRAPHY; PEPTIDES; PLASMA (HUMAN); PLASMAS;

ALZHEIMER'S DISEASE; ANTIBODY-BASED IMMUNOASSAYS; DETECTION AND QUANTIFICATIONS; LIMIT OF QUANTIFICATIONS; QUANTITATIVE MEASUREMENT; REVERSED-PHASE LIQUID CHROMATOGRAPHY; SELECTED REACTION MONITORING; TRIPLICATE MEASUREMENT;

MASS SPECTROMETRY;

AMYLOID BETA PROTEIN; PLASMA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH PH REVERSED PHASE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; SELECTED REACTION MONITORING MASS SPECTROMETRY; AMINO ACID SEQUENCE; ANIMAL; BLOOD; GENETICS; MOLECULAR GENETICS; PROCEDURES; STANDARDS; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOLOGICAL MARKERS; HUMANS; MASS SPECTROMETRY; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS;

EID: 84905088511     PISSN: 00032670     EISSN: 18734324     Source Type: Journal    
DOI: 10.1016/j.aca.2014.06.024     Document Type: Article

References (53)

1. Alzheimer A., Stelzmann R.A., Schnitzlein H.N., Murtagh F.R. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin. Anat. 1995, 8:429-431.
2. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
3. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
4. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 2000, 57:100-105.
5. Kuo Y.M., Emmerling M.R., Lampert H.C., Hempelman S.R., Kokjohn T.A., Woods A.S., Cotter R.J., Roher A.E. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 1999, 257:787-791.
6. Kuo Y.M., Kokjohn T.A., Kalback W., Luehrs D., Galasko D.R., Chevallier N., Koo E.H., Emmerling M.R., Roher A.E. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem. Biophys. Res. Commun. 2000, 268:750-756.
7. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996, 2:864-870.
8. JM, Moreno R., Alio J.L. Postoperative fibrinoid reaction in extracapsular surgery with intraocular lens implantation in diabetic retinopathy patients. Ocul. Immunol. Inflamm. 1993, 1:125-130.
9. J.M Potential new Alzheimer's test. Science 1992, 256:1279.
10. Jensen M., Schroder J., Blomberg M., Engvall B., Pantel J., Ida N., Basun H., Wahlund L.O., Werle E., Jauss M., Beyreuther K., Lannfelt L., Hartmann T. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol. 1999, 45:504-511.
11. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R., et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 1995, 38:643-648.
12. Shanmugam J.M. The bacteriology of diabetic foot ulcers, with a special reference to multidrug resistant strains. J. Clin. Diagn. Res. 2013, 7:441-445.
13. Kim J.S., Lee Y., Lee M.Y., Shin J., Han J.M., Yang E.G., Yu M.H., Kim S., Hwang D., Lee C. Multiple reaction monitoring of multiple low-abundance transcription factors in whole lung cancer cell lysates. J. Proteome Res. 2013, 12:2582-2596.
14. Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5:573-588.
15. Picotti P., Rinner O., Stallmach R., Dautel F., Farrah T., Domon B., Wenschuh H., Aebersold R. High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat. Method 2010, 7:43-46.
16. Kuzyk M.A., Smith D., Yang J.C., Cross T.J., Jackson A.M., Hardie D.B., Anderson N.L., Borchers C.H. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics 2009, 8:1860-1877.
17. Wang Q., Chaerkady R., Wu J., Hwang H.J., Papadopoulos N., Kopelovich L., Maitra A., Matthaei H., Eshleman J.R., Hruban R.H., Kinzler K.W., Pandey A., Vogelstein B. Mutant proteins as cancer-specific biomarkers. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2444-2449.
18. Shi T., Fillmore T.L., Sun X., Zhao R., Schepmoes A.A., Hossain M., Xie F., Wu S., Kim J.S., Jones N., Moore R.J., Pasa-Tolic L., Kagan J., Rodland K.D., Liu T., Tang K., Camp D.G., Smith R.D., Qian W.J. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:15395-15400.
19. Mohamadi M.R., Svobodova Z., Verpillot R., Esselmann H., Wiltfang J., Otto M., Taverna M., Bilkova Z., Viovy J.L. Microchip electrophoresis profiling of Abeta peptides in the cerebrospinal fluid of patients with Alzheimer's disease. Anal. Chem. 2010, 82:7611-7617.
20. Kosicek M., Kirsch S., Bene R., Trkanjec Z., Titlic M., Bindila L., Peter-Katalinic J., Hecimovic S. Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer's disease patients - a pilot study. Anal. Bioanal. Chem. 2010, 398:2929-2937.
21. Razavi M., Johnson L.D., Lum J.J., Kruppa G., Anderson N.L., Pearson T.W. Quantification of a proteotypic peptide from protein C inhibitor by liquid chromatography-free SISCAPA-MALDI mass spectrometry: application to identification of recurrence of prostate cancer. Clin. Chem. 2013, 59:1514-1522.
22. Razavi M., Frick L.E., LaMarr W.A., Pope M.E., Miller C.A., Anderson N.L., Person T.W. High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J. Proteome Res. 2012, 11:5642-5649.
23. Lame M.E., Chambers E.E., Blatnik M. Quantitation of amyloid beta peptides Abeta(1-38), Abeta(1-40), and Abeta(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry. Anal. Biochem. 2011, 419:133-139.
24. Sarasa L., Allue J.A., Pesini P., Gonzalez-Martinez A., Sarasa M. Identification of beta-amyloid species in canine cerebrospinal fluid by mass spectrometry. Neurobiol. Aging 2013, 34:2125-2132.
25. Oe T., Ackermann B.L., Inoue K., Berna M.J., Garner C.O., Gelfanova V., Dean R.A., Siemers E.R., Holtzman D.M., Farlow M.R., Blair I.A. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20:3723-3735.
26. Wong M., Schlaggar B.L., Buller R.S., Storch G.A., Landt M. Cerebrospinal fluid protein concentration in pediatric patients: defining clinically relevant reference values. Arch. Pediatr. Adolesc. Med. 2000, 154:827-831.
27. Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin. Wochenschr. 1974, 52:1158-1164.
28. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1:845-867.
29. Yang F., Shen Y., Camp D.G., Smith R.D. High-pH reversed-phase chromatography with fraction concatenation for 2D proteomic analysis. Expert Rev. Proteomics 2012, 9:129-134.
30. Whiteaker J.R., Lin C., Kennedy J., Hou L., Trute M., Sokal I., Yan P., Schoenherr R.M., Zhao L., Voytovich U.J., Kelly-Spratt K.S., Krasnoselsky A., Gafken P.R., Hogan J.M., Jones L.A., Wang P., Amon L., Chodosh L.A., Nelson P.S., McIntosh M.W., Kemp C.J., Paulovich A.G. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 2011, 29:625-634.
31. Halvey P.J., Ferrone C.R., Liebler D.C. GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples. J. Proteome Res. 2012, 11:3908-3913.
32. Remily-Wood E.R., Liu R.Z., Xiang Y., Chen Y., Thomas C.E., Rajyaguru N., Kaufman L.M., Ochoa J.E., Hazlehurst L., Pinilla-Ibarz J., Lancet J., Zhang G., Haura E., Shibata D., Yeatman T., Smalley K.S., Dalton W.S., Huang E., Scott E., Bloom G.C., Eschrich S.A., Koomen J.M. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin. Appl. 2011, 5:383-396.
33. Xiang Y., Remily-Wood E.R., Oliveira V., Yarde D., He L., Cheng J.Q., Mathews L., Boucher K., Cubitt C., Perez L., Gauthier T.J., Eschrich S.A., Shain K.H., Dalton W.S., Hazlehurst L., Koomen J.M. Monitoring a nuclear factor-kappaB signature of drug resistance in multiple myeloma. Mol. Cell. Proteomics 2011, 10. M110 005520.
34. Choi J.W., Kim H.Y., Jeon M., Kim D.J., Kim Y. Efficient access to highly pure beta-amyloid peptide by optimized solid-phase synthesis. Amyloid 2012, 19:133-137.
35. Shi T.J., Fillmore T.L., Sun X.F., Zhao R., Schepmoes A.A., Hossain M., Xie F., Wu S., Kim J.S., Jones N., Moore R.J., Pasa-Tolic L., Kagan J., Rodland K.D., Liu T., Tang K.Q., Camp D.G., Smith R.D., Qian W.J. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:15395-15400.
36. Schilling B., Rardin M.J., MacLean B.X., Zawadzka A.M., Frewen B.E., Cusack M.P., Sorensen D.J., Bereman M.S., Jing E., Wu C.C., Verdin E., Kahn C.R., Maccoss M.J., Gibson B.W. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol. Cell. Proteomics 2012, 11:202-214.
37. Krokhin O.V., Spicer V. Peptide retention standards and hydrophobicity indexes in reversed-phase high-performance liquid chromatography of peptides. Anal. Chem. 2009, 81:9522-9530.
38. O'Brien R.J., Wong P.C. Amyloid precursor protein processing and Alzheimer's disease. Ann. Rev. Neurosci. 2011, 34:185-204.
39. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
40. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.
41. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005, 28:202-208.
42. Tanzi R.E., Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001, 32:181-184.
43. Matsubara E., Frangione B., Ghiso J. Characterization of apolipoprotein J-Alzheimer's A beta interaction. J. Biol. Chem. 1995, 270:7563-7567.
44. Piccinni A., Origlia N., Veltri A., Vizzaccaro C., Marazziti D., Catena-Dell'osso M., Conversano C., Moroni I., Domenici L., Dell'osso L. Plasma beta-amyloid peptides levels: a pilot study in bipolar depressed patients. J. Affec. Disord. 2012, 138:160-164.
45. Pesaresi M., Lovati C., Bertora P., Mailland E., Galimberti D., Scarpini E., Quadri P., Forloni G., Mariani C. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 2006, 27:904-905.
46. Flicker L., Martins R.N., Thomas J., Acres J., Taddei K., Vasikaran S.D., Norman P., Jamrozik K., Almeida O.P. B-vitamins reduce plasma levels of beta amyloid. Neurobiol. Aging 2008, 29:303-305.
47. Schupf N., Patel B., Pang D., Zigman W.B., Silverman W., Mehta P.D., Mayeux R. Elevated plasma beta-amyloid peptide A beta(42) levels, incident dementia, and mortality in down syndrome. Arch. Neurol. 2007, 64:1007-1013.
48. Hoglund K., Wiklund O., Vanderstichele H., Eikenberg O., Vanmechelen E., Blennow K. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch. Neurol. 2004, 61:333-337.
49. Portelius E., Westman-Brinkmalm A., Zetterberg H., Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome Res. 2006, 5:1010-1016.
50. Roher A.E., Esh C.L., Kokjohn T.A., Castano E.M., Van Vickle G.D., Kalback W.M., Patton R.L., Luehrs D.C., Daugs I.D., Kuo Y.M., Emmerling M.R., Soares H., Quinn J.F., Kaye J., Connor D.J., Silverberg N.B., Adler C.H., Seward J.D., Beach T.G., Sabbagh M.N. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. J. Alzheimers Assoc. 2009, 5:18-29.
51. Takahashi E., Howe A., Vesterqvist O., Lin Z. Quantitation of amyloid beta peptides in CSF by surface enhanced MALDI-TOF. Method Mol. Biol. 2012, 818:227-236.
52. Schonknecht P., Lutjohann D., Pantel J., Bardenheuer H., Hartmann T., von Bergmann K., Beyreuther K., Schroder J. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci. Lett. 2002, 324:83-85.
53. Fukuyama R., Izumoto T., Fushiki S. The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia. Eur. Neurol. 2001, 46:35-38.